Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05337241 · ClinicalTrials.gov registry record · NA

Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT

A NA study of Refractory Ventricular Tachycardia, sponsored by Thermedical.

Recruiting
Registry status
NA
Development phase
130
Enrollment target
7
Study locations

NCT05337241 is a NA study of Refractory Ventricular Tachycardia that is actively recruiting participants, run by Thermedical. The registered enrollment target is 130 participants. The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05337241, a NA study of Refractory Ventricular Tachycardia, is actively recruiting participants, sponsored by Thermedical.

RECRUITING
Registry status
NA
Development phase
130 participants
Enrollment target
7
Study locations

Study Summary

The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) refractory to drug therapy and conventional (approved) catheter ablation. Subjects with recurrent, SMVT refractory to drug therapy and conventional catheter ablation who are not eligible for, or will not likely benefit from repeat endocardial ablation using an approved catheter.

Interventions

  • DEVICE Saline Enhanced Radiofrequency (SERF) Ablation

Study Locations (7)

Quebec

  • Montreal Heart Institute - Institut de Cardiologie de Montréal - Montreal
  • Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec - Québec

Alabama

  • University of Alabama at Birmingham - Birmingham

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia

South Carolina

  • Medical University of South Carolina - Charleston

Tennessee

  • Vanderbilt University Medical Center - Nashville

Utah

  • Intermountain Healthcare - Salt Lake City

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-08-09
Est. Completion 2027-06-30
Phase NA

Sponsor

Thermedical

2 total trials

What the Registry Record Tells You About NCT05337241

The ClinicalTrials.gov registry entry for NCT05337241 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thermedical, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Refractory Ventricular Tachycardia appearing as the primary indexed condition, and to 1 intervention - of which Saline Enhanced Radiofrequency (SERF) Ablation is the first listed.

NCT05337241 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Quebec, Alabama, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05337241 about?

NCT05337241 is a clinical study titled "Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT". The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) refractory to drug therapy and conventional (approved) catheter ablation. Subjects with recurrent, SMVT refractory to drug therapy and conven...

What is the current status of trial NCT05337241?

This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-08-09. Estimated completion is 2027-06-30.

What conditions does trial NCT05337241 study?

This clinical trial studies the following conditions: Refractory Ventricular Tachycardia.

What interventions are being tested in trial NCT05337241?

The interventions under investigation include: Saline Enhanced Radiofrequency (SERF) Ablation (DEVICE).

Who is sponsoring clinical trial NCT05337241?

This trial is sponsored by Thermedical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05337241 being conducted?

This trial has 7 study locations across Alabama, Pennsylvania, South Carolina, Tennessee, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.